2021 Fiscal Year Final Research Report
A novel nucleic acid medicine (anaphylaxis preventive drug) using innovative receptor synthesis technology
Project/Area Number |
18K16541
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 55060:Emergency medicine-related
|
Research Institution | Saiseikai Research Institute of Health Care and Welfare (2021) Ehime University (2018-2020) |
Principal Investigator |
SUZUKI YASUYUKI 社会福祉法人恩賜財団済生会(済生会保健・医療・福祉総合研究所研究部門), 済生会保健・医療・福祉総合研究所研究部門, 客員研究員 (10745144)
|
Project Period (FY) |
2018-04-01 – 2022-03-31
|
Keywords | アナフィラキシー / 周術期管理 / 麻酔 / 無細胞蛋白質合成 / 核酸医薬品 |
Outline of Final Research Achievements |
Various substances used in surgery sometimes cause severe allergic reactions. Generally, severe allergic reactions occur when the causative substance stimulates mast cells via specific IgE antibodies, releasing substances such as histamine. Recently, a new pathway that directly stimulates Mas-related G protein-coupled receptor X2 (MRGPRX2) has been found to cause allergic reactions. However, no drug that specifically inhibits this pathway has been found. Therefore, we developed a nucleic acid drug aptamer using MRGPRX2 synthesized by cell-free protein synthesis system as a template, and showed that the aptamer inhibited histamine release from cultured mast cells. This finding could be a seed for a new allergy drug.
|
Free Research Field |
周術期管理
|
Academic Significance and Societal Importance of the Research Achievements |
本研究で得られた核酸医薬品は、これまでのアレルギー治療薬と全く違う作用機序でアレルギー反応を抑える薬に結びつく重要なシードである。また、このシードを作成するに際に、培養細胞に合成させた蛋白質では無く、無細胞蛋白質合成系で合成した蛋白質を鋳型とした点が新しく、今後様々な核酸医薬品を容易に発見することが可能になってくるかもしれない。
|